论文信息 - FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia. - 字舞流文

FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia.

Jiang Liu | R. Pazdur | C. Ko | A. Farrell | K. Norsworthy | D. Przepiorka | Jee Eun Lee | C. John | Kelly J. Norsworthy